NewsBenzingaOruka Therapeutics宣布其EVERLAST-A第2A期试验中ORKA-001治疗中度至重度银屑病的第28周结果;ORKA-001在第28周保持了良好的安全性和耐受性;预计在2026年第四季度公布16周的EVERLAST-B数据 Oruka Therapeutics宣布其EVERLAST-A第2A期试验中ORKA-001治疗中度至重度银屑病的第28周结果;ORKA-001在第28周保持了良好的安全性和耐受性;预计在2026年第四季度公布16周的EVERLAST-B数据 Benzinga 2026.09.23 11:08 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3